Oncolytics Biotech Files 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateJun 27, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, routine-report

Related Tickers: ONC

TL;DR

Oncolytics Biotech (ONC) filed a 6-K, just a routine update for foreign issuers. Nothing major here.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on June 27, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding the company's status as a foreign private issuer. It confirms their adherence to SEC reporting requirements.

Risk Assessment

Risk Level: low — This filing is a standard procedural report for a foreign private issuer and does not contain new financial or operational information that would typically indicate significant risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, typically to provide information that the registrant makes or is required to make public in its home country or to send or make public to its security holders.

What is the filing date of this 6-K report?

The filing date of this 6-K report is June 27, 2024.

Where is Oncolytics Biotech Inc. headquartered?

Oncolytics Biotech Inc. is headquartered in Calgary, Alberta, Canada.

What is the SEC file number for Oncolytics Biotech Inc.?

The SEC file number for Oncolytics Biotech Inc. is 001-38512.

Does Oncolytics Biotech Inc. file an annual report on Form 20-F or 40-F?

Oncolytics Biotech Inc. indicates it files its annual reports under cover of Form 20-F.

Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-06-27 12:16:54

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date June 27, 2024 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing